Paper Details

  1. Home
  2. Paper Details

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

Author: MillerR G, MitchellJ D, MooreD H

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Riluzole 100 mg per day appears to be modestly effective in prolonging survival for patients with ALS.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Riluzole has been approved for treatment of patients with amyotrophic lateral sclerosis (ALS) in some countries but not others. Questions persist about its clinical utility because of high cost, modest efficacy and concern over adverse effects. OBJECTIVES: To examine the efficacy of ril...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD001447

データ提供：米国国立医学図書館（NLM）

Riluzole for Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND)

This study examines the effectiveness of riluzole, a medication used to treat amyotrophic lateral sclerosis (ALS), in prolonging survival and delaying the need for life-sustaining interventions. The researchers conducted a meta-analysis of two randomized controlled trials, assessing the effects of riluzole on survival, functional decline, and quality of life in patients with ALS. The findings suggest that riluzole may offer a modest survival advantage for individuals with ALS.

Riluzole and ALS Survival

The meta-analysis revealed a statistically significant reduction in mortality at 12 months in patients treated with riluzole compared to those receiving placebo. The study also indicated that riluzole may delay the need for life-sustaining interventions, such as tracheostomy and mechanical ventilation.

ALS Treatment and Prognosis

The study provides evidence that riluzole may offer a modest survival benefit for individuals with ALS, potentially extending their lifespan and improving their quality of life. However, the research also highlights the need for further investigation to fully understand the long-term effects of riluzole and explore potential strategies for enhancing its efficacy.

Dr.Camel's Conclusion

Imagine a camel caravan traveling through a vast desert, facing a debilitating disease that weakens the camels and threatens their survival. Riluzole is like a potent elixir that can help the camels maintain their strength and endurance, allowing them to continue their journey for a longer time. This research suggests that riluzole may offer a valuable tool for managing ALS, potentially extending the lives of those affected by this debilitating disease.
Date :
  1. Date Completed 2002-04-19
  2. Date Revised 2020-05-11
Further Info :

Pubmed ID

11687111

DOI: Digital Object Identifier

10.1002/14651858.CD001447

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.